COVAXHIV: COVID-19 Vaccine Immunogenicity and Safety in People Living with HIV in Canada

375 participants living with HIV were recruited from clinics in Montreal, Ottawa, Toronto, and Vancouver between April 2021 and January 2022. Data includes demographics, health behaviors, vaccination history, and serology results from 4,548 serum and plasma samples collected up to October 2022. This dataset, contributed to the CITF Databank by Aslam Anis, focuses on immunogenicity and safety outcomes following third and fourth COVID 19 vaccine doses.

Use Cases

• Modeling vaccine immunogenicity over time based on longitudinal serology and neutralization data.
• Assessing risk factors for COVID-19 infection and hospitalization based on demographic and exposure variables.
• Comparing immune response durability after third and fourth vaccine doses using serology and cellular immunity data.
• Analyzing associations between chronic health conditions and vaccine outcomes based on general health variables.

Strengths

• Includes 4,548 serum and plasma samples for detailed serological analysis.
• Longitudinal follow-up data for 344 participants over up to 12 months post third dose.
• Variables cover demographics, health behaviors, vaccination history, and multiple immune response measures.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is limited to participants from four major Canadian cities, which may affect generalizability.

Provenance

Source

Borealis Harvested Dataverse, contributed by Aslam Anis to the CITF Databank.

Collection Method

Cohort study with participants recruited from clinics and social media, using standardized questionnaires and serological sampling.

Time Range

Participant enrollment from April 2021 to January 2022; sample collection from November 2020 to October 2022.

Freshness

Last updated 2026-04-25 04:15:43; freshness should be verified.

Geography

Participants recruited from clinics in Montreal, Ottawa, Toronto, and Vancouver, Canada.